Login to Your Account



Other news to note


Wednesday, February 19, 2014

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said data showing that MM-141 is able to inhibit oncogenic signaling through the PI3K/AKT/mTOR pathway was published in Molecular Cancer Therapeutics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription